Wang Shuailiang, Zhou Xin, Xu Xiaoxia, Ding Jin, Liu Teli, Jiang Jinquan, Li Nan, Zhu Hua, Yang Zhi
Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
Front Oncol. 2021 Mar 11;11:651005. doi: 10.3389/fonc.2021.651005. eCollection 2021.
This study aims to further explore dynamic Ga-FAPI-04 PET/CT imaging of healthy Chinese subjects and lung cancer patients. Moreover, the variability of Ga-FAPI-04 uptake in normal organs was measured to provide a basis for analyzing its biological distribution, interpreting auxiliary images, determining the reliability of image quantification, and monitoring treatment. Six patients (3 subjects without tumors and 3 lung cancer patients) separately underwent Ga-FAPI-04 and 2-[F]FDG PET/CT imaging within 1 week. The biodistribution and internal radiation dosimetry were reported and compared with data previously obtained from Caucasian patients. Moreover, the mean SUV (standardized uptake value) was normalized to body mass or to lean body mass (SUL), and the coefficients of variation (CVs) were calculated and compared for each volume of interest. The average whole-body effective dose was calculated to be 1.27E-02 mSv/MBq, which was comparable with previously reported results of Ga-FAPI-04 probes. Furthermore, the SUVmean was slightly higher than the SULmean in most organs; however, the CV of the SULmean for most organs was higher than that of the SUVmean at later time points. In the liver, the CV of the SUVmean was lower (12.7%) than that of the SULmean and was similar to the CV for corresponding 2-[F]FDG PET/CT value (11.8%). In addition, Ga-FAPI-04 PET/CT showed good efficacy for diagnosing lung cancer patients in this study. A comparison of the radiation dosimetry obtained before from a Caucasian population demonstrated no clinically significant differences between these two populations after Ga-FAPI-04 injection. The variability in most organs was slightly lower for SUVmean than for SULmean, suggesting that SUVmean may be the preferable parameter for quantifying images obtained with Ga-FAPI-04. In addition, Ga-FAPI-04 PET/CT imaging is expected to be a promising tool for diagnosing lung cancer.
本研究旨在进一步探索健康中国受试者和肺癌患者的镓（Ga）-FAPI-04正电子发射断层显像/计算机断层扫描（PET/CT）动态成像。此外，测量了正常器官中Ga-FAPI-04摄取的变异性，为分析其生物分布、解读辅助图像、确定图像定量的可靠性以及监测治疗提供依据。6例患者（3例无肿瘤受试者和3例肺癌患者）在1周内分别接受了Ga-FAPI-04和2-[F]氟代脱氧葡萄糖（FDG）PET/CT成像。报告了生物分布和体内辐射剂量测定结果，并与先前从白种人患者获得的数据进行了比较。此外，将平均标准化摄取值（SUV）归一化至体重或去脂体重（SUL），并计算每个感兴趣体积的变异系数（CV）并进行比较。计算出的平均全身有效剂量为1.27E-02毫希沃特/兆贝可，与先前报道的Ga-FAPI-04探针结果相当。此外，在大多数器官中，SUV均值略高于SUL均值；然而，在较晚时间点，大多数器官的SUL均值CV高于SUV均值CV。在肝脏中，SUV均值的CV（12.7%）低于SUL均值的CV，且与相应的2-[F]FDG PET/CT值的CV（11.8%）相似。此外，在本研究中，Ga-FAPI-04 PET/CT对肺癌患者显示出良好的诊断效能。与先前从白种人群获得的辐射剂量测定结果比较表明，注射Ga-FAPI-04后这两个人群之间无临床显著差异。对于SUV均值，大多数器官的变异性略低于SUL均值，这表明SUV均值可能是量化Ga-FAPI-04获得图像的更优参数。此外，Ga-FAPI-04 PET/CT成像有望成为诊断肺癌的一种有前景的工具。
